Navana Pharma posts 50% profit growth in H1

Navana Pharmaceuticals has posted a year-on-year significant improvement in its financial performance for the first six months of the current 2025-26 fiscal year, driven by higher sales, improved profitability, and stronger operating cash flows. 

According to the unaudited financial statements for July to December, the net profit of the company stood at Tk36.27 crore, which is 50.22% higher than Tk24.14 crore compared to the same period of the previous year.

On Thursday, the share price of the company increased by 2.67% to Tk57.60 on the Dhaka Stock Exchange. 

In the July to December period, the company's diluted earnings per share (EPS) rose to Tk3.35, which was Tk2.25 in the previous period of FY25. 

In October to December quarter, the company's diluted earnings per share (EPS) rose to Tk1.65 for the October-December 2025 quarter, compared to Tk1.00 in the same quarter of the previous year. This represents a year-on-year growth of 65%, reflecting improved operational efficiency and cost management.

The company attributed the earnings growth to a combination of increased net sales, improved gross profit margins, and a reduction in finance costs. Higher revenue generation, supported by better market demand and efficient production planning, played a key role in boosting profitability during the reporting period. 

At the same time, lower borrowing costs and prudent financial management helped ease pressure on expenses, further supporting the bottom line.

In addition to earnings growth, the company also recorded a substantial improvement in its operating cash flow position. Net operating cash flow per share increased sharply to Tk8.11 for the July-December 2025 period, compared to Tk3.16 in the same period last year.

The rise in operating cash flow was primarily driven by higher cash receipts from customers, which exceeded cash payments made to vendors and other operating expenses during the period. 

Meanwhile, the company's net asset value (NAV) per share also showed steady growth. NAV per share stood at Tk48.32 as of 31 December 2025, compared to Tk45.29 as of 30 June 2025. 

The company stated that it remains focused on maintaining operational efficiency, managing costs prudently, and strengthening its financial position amid evolving market conditions. 

Incorporated in 1986 in Bangladesh, Navana Pharma produces both human and animal drugs.

The veterinary division manufactures and markets more than 123 high-quality medicines and feed supplements for different segments, including poultry, dairy, and aqua products.

On the other hand, the human health division produces more than 277 drugs – tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, eye drops, creams, ointments, etc.

Navana Pharma sells these products in the domestic and international markets. It exports products to 15 countries.